• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will QURE’s AMT-130 Regulatory Momentum Offset Mounting Losses And Share Dilution Risk?

    Simply Wall St·07/30/2026 08:16:55
    Listen to the news
    • In the past week, uniQure N.V. reported Q2 2026 results showing revenue of US$5.84 million alongside a much larger quarterly net loss of US$81.06 million, while also filing a US$12.83 million shelf registration for 350,000 ordinary shares tied to its employee share plan.
    • At the same time, the company advanced its regulatory plans for AMT-130 in Huntington’s disease and highlighted promising early data in epilepsy and Fabry programs, framing a contrast between widening losses and progress in its gene therapy pipeline.
    • We’ll now examine how the regulatory momentum around AMT-130 reshapes uniQure’s earlier investment narrative and risk-reward profile.

    Find 49 companies with promising cash flow potential yet trading below their fair value.

    uniQure Investment Narrative Recap

    To own uniQure today, you have to believe that its gene therapy platform, and especially AMT-130 in Huntington’s disease, can eventually justify ongoing heavy losses and repeated equity raises. The latest quarter deepens the near term financial risk, with a larger net loss and continued dilution, but it does not fundamentally change the key near term catalyst, which is the planned AMT-130 BLA submission and related regulatory decisions.

    The most relevant piece of recent news is uniQure’s alignment with the FDA on an accelerated approval pathway for AMT-130, with a BLA targeted for Q3 2026. This regulatory clarity sits directly against rising operating losses, putting more weight on whether regulators ultimately accept the three year Phase I/II data and the proposed confirmatory trial design as sufficient for approval and, later, for broader adoption.

    Yet behind this apparent momentum, investors should still be aware that...

    Read the full narrative on uniQure (it's free!)

    uniQure's narrative projects $378.0 million revenue and $71.5 million earnings by 2029.

    Uncover how uniQure's forecasts yield a $64.47 fair value, a 61% upside to its current price.

    Exploring Other Perspectives

    QURE 1-Year Stock Price Chart
    QURE 1-Year Stock Price Chart

    By contrast, the lowest ranked analysts were already assuming revenue of only about US$41.0 million and no profitability by 2028, highlighting how concerns about tighter FDA standards and prolonged losses could become more pronounced if the latest larger net loss and ongoing AMT 130 trial demands lead them to revisit those cautious assumptions.

    Explore 5 other fair value estimates on uniQure - why the stock might be worth over 10x more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Searching For A Fresh Perspective?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.